Craig-Hallum Reiterates a Buy Rating on Bioventus (BVS), Sets a $15 PT

Bioventus Inc. (NASDAQ:BVS) is one of the best medical device stocks to buy according to analysts. On August 7, Craig-Hallum analyst Chase Knickerbocker reiterated a Buy rating on Bioventus Inc. (NASDAQ:BVS) and set a price target of $15.00.

The analyst gave the rating after Bioventus Inc. (NASDAQ:BVS) reported its fiscal Q2 results on August 6, with reported revenue of $147.7 million declining 2.4% and organic revenue advancing 6.2%.

Diluted earnings per share for Q2 was $0.11 compared to a diluted loss per share of $0.40 in the prior-year period.

Bioventus Inc. (NASDAQ:BVS) also reported cash from operations of $25.9 million and non-GAAP earnings of $0.21 per share.

Bioventus Inc. (NASDAQ:BVS) is a medical technology company that develops and commercializes proprietary orthobiologic products to treat musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP.

While we acknowledge the potential of BVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.